BEIJING (Reuters) – A COVID-19 vaccine from Sinopharm unit Beijing Institute of Biological Products has obtained approval to be used on people aged between three and 17 in China, a disease control official said on Friday.
Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention, was speaking to reporters at a news briefing.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Edmund Blair)
